Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 397,390,784
  • Shares Outstanding, K 2,406,679
  • Annual Sales, $ 85,159 M
  • Annual Income, $ 35,153 M
  • EBIT $ 15,667 M
  • EBITDA $ 23,153 M
  • 60-Month Beta 0.52
  • Price/Sales 4.65
  • Price/Cash Flow 12.04
  • Price/Book 5.53

Options Overview Details

View History
  • Implied Volatility 15.76% ( +0.84%)
  • Historical Volatility 10.50%
  • IV Percentile 41%
  • IV Rank 32.47%
  • IV High 22.48% on 08/05/24
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.39
  • Today's Volume 26,968
  • Volume Avg (30-Day) 24,719
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 318,021
  • Open Int (30-Day) 364,507

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 2.04
  • Number of Estimates 7
  • High Estimate 2.33
  • Low Estimate 1.94
  • Prior Year 2.29
  • Growth Rate Est. (year over year) -10.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
158.77 +2.55%
on 10/04/24
166.75 -2.35%
on 10/15/24
-1.33 (-0.81%)
since 09/20/24
3-Month
151.57 +7.43%
on 07/23/24
168.85 -3.57%
on 09/04/24
+8.14 (+5.26%)
since 07/19/24
52-Week
143.13 +13.76%
on 04/18/24
168.85 -3.57%
on 09/04/24
+9.83 (+6.42%)
since 10/20/23

Most Recent Stories

More News
Stock market today: Wall Street pulls back from its records

U.S. stocks edged back from their all-time highs as some of the steam came out of Wall Street’s long, record-breaking rally

NFLX : 772.07 (+1.07%)
KO : 69.45 (-1.41%)
T : 21.66 (-0.87%)
LEN : 180.63 (-4.39%)
IBM : 231.75 (-0.19%)
$SPX : 5,853.98 (-0.18%)
GM : 48.93 (-0.51%)
JNJ : 162.83 (-1.39%)
KVUE : 22.92 (+5.52%)
$DOWI : 42,931.60 (-0.80%)
$IUXX : 20,361.47 (+0.18%)
BA : 159.82 (+3.11%)
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer healthcare (CHC)...

JNJ : 162.83 (-1.39%)
GSK : 38.16 (-1.01%)
PFE : 28.93 (-0.99%)
SNY : 53.66 (-2.31%)
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year

Investors looking for dividend stocks at reasonable valuations have come to the right place.

CVX : 150.88 (+0.09%)
JNJ : 162.83 (-1.39%)
$DOWI : 42,931.60 (-0.80%)
DOW : 52.21 (-1.69%)
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever

These companies' longtime shareholders have generally been rewarded.

ABT : 116.99 (-2.01%)
JNJ : 162.83 (-1.39%)
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs

This week, Johnson & Johnson JNJ began the third-quarter earnings season for the drug and biotech sector. The FDA granted approval to a few new drugs, which included Pfizer’s PFE gene therapy for hemophilia,...

JNJ : 162.83 (-1.39%)
ABBV : 186.54 (-1.23%)
RHHBY : 39.4000 (-0.40%)
PFE : 28.93 (-0.99%)
SNY : 53.66 (-2.31%)
J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?

On Oct. 15, J&J JNJ announced strong third-quarter results, beating estimates for both earnings and sales. The Innovative Medicine segment outperformed expectations. However, the MedTech segment underperformed...

NVO : 117.33 (-0.64%)
JNJ : 162.83 (-1.39%)
LLY : 906.13 (-1.29%)
KVUE : 22.92 (+5.52%)
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now

These stocks could deliver big over the long term.

ABT : 116.99 (-2.01%)
JNJ : 162.83 (-1.39%)
PFE : 28.93 (-0.99%)
ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike

Johnson & Johnson JNJ infused positive optimism for the broader healthcare sector after posting solid third-quarter 2024 earnings on Oct. 15. The world's biggest healthcare products maker continued with...

XLV : 151.33 (-1.18%)
JNJ : 162.83 (-1.39%)
IHE : 70.81 (-1.46%)
IYH : 63.93 (-1.19%)
PPH : 93.63 (-1.10%)
FTXH : 28.47 (-1.18%)
This Magnificent Dividend Stock Is as Healthy as It Gets

Johnson & Johnson's latest financial checkup shows it's still in excellent health.

JNJ : 162.83 (-1.39%)
Stock Market News for Oct 16, 2024

Market NewsWall Street ended lower on Tuesday as investors digested Mary Daly's remarks during a meeting at New York University, regarding interest rates. Market participants also evaluated Q3 earnings...

BAC : 41.76 (-1.32%)
JNJ : 162.83 (-1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 167.56
2nd Resistance Point 166.40
1st Resistance Point 164.62
Last Price 162.83
1st Support Level 161.68
2nd Support Level 160.52
3rd Support Level 158.74

See More

52-Week High 168.85
Last Price 162.83
Fibonacci 61.8% 159.02
Fibonacci 50% 155.99
Fibonacci 38.2% 152.96
52-Week Low 143.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar